LLS engages with Federal Regulatory agencies, such as the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS), as well as local state regulators who govern rules around insurance and access.  The LLS regulatory policy covers many issues, but below are some of the most recent concerns that LLS is focused on:

• Encouraging patient participation in the drug approval process at the FDA
• Streamlining expanded access to investigational drugs
• Ensuring patients have access to the most accurate, safe, and effective diagnostic tools

If you have any further questions about LLS' Regulatory policy platform, please email Ernest Voyard, Senior Director, Regulatory Affairs.